Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biotechnology company focused on developing innovative non-opioid pain medicines with best-in-class profiles. The company's mission is to provide effective, rapid-acting pain relief without the risk of addiction, targeting pain at its source. Supported by leading investors, Latigo leverages advanced technologies and human genetics to validate its drug targets, aiming to transform pain management and address the opioid epidemic.
Industries
Nr. of Employees
small (1-50)
Latigo Biotherapeutics
1300 Rancho Conejo Blvd, Suite 305, Thousand Oaks, CA 91320
Products
Oral selective Nav1.8 inhibitor — clinical candidate for acute pain
An orally administered selective small-molecule inhibitor of the Nav1.8 sodium channel developed to block peripheral pain signaling with rapid absorption and a favorable Phase 1 safety and PK profile; progressed through first-in-human studies and received expedited regulatory designation.
Oral selective Nav1.8 inhibitor — clinical candidate for chronic pain
An orally administered selective small-molecule Nav1.8 inhibitor advanced into Phase 1 to evaluate safety, tolerability, and pharmacokinetics for chronic pain indications using SAD and MAD study designs.
Oral selective Nav1.8 inhibitor — clinical candidate for acute pain
An orally administered selective small-molecule inhibitor of the Nav1.8 sodium channel developed to block peripheral pain signaling with rapid absorption and a favorable Phase 1 safety and PK profile; progressed through first-in-human studies and received expedited regulatory designation.
Oral selective Nav1.8 inhibitor — clinical candidate for chronic pain
An orally administered selective small-molecule Nav1.8 inhibitor advanced into Phase 1 to evaluate safety, tolerability, and pharmacokinetics for chronic pain indications using SAD and MAD study designs.
Services
End-to-end discovery workflows including target selection guided by human genetics, structure-based and AI/ML-supported design, in vitro electrophysiology, biomarker development, and preclinical biodistribution to support clinical translation.
Design and conduct of first-in-human single- and multiple-ascending dose trials with PK, safety, tolerability, relative bioavailability, and food effect assessments.
End-to-end discovery workflows including target selection guided by human genetics, structure-based and AI/ML-supported design, in vitro electrophysiology, biomarker development, and preclinical biodistribution to support clinical translation.
Design and conduct of first-in-human single- and multiple-ascending dose trials with PK, safety, tolerability, relative bioavailability, and food effect assessments.
Expertise Areas
- Clinical trial management
- Ion channel drug discovery (Nav1.8-focused)
- Translational science and biomarker development
- Medicinal chemistry and lead optimization
Key Technologies
- Voltage-gated sodium channel targeting (Nav1.8)
- Structure-based drug design
- AI/ML-driven drug design
- Patch clamp electrophysiology
News & Updates
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board. Proceeds support advancement of company’s Nav1.8 inhibitor clinical programs and development of broader pipeline.
Latigo announced positive Phase 1 results for LTG-001, a potential best-in-class non-opioid Nav1.8 inhibitor, which was well tolerated with rapid absorption. The FDA granted Fast Track designation to LTG-001.
Timothy P. Walbert, with 30 years of biopharmaceutical industry experience and recent leadership at Horizon Therapeutics, has been appointed as chair of Latigo’s board of directors.
Latigo announced the first participant has been dosed in its Phase 1 trial of LTG-305, a potential best-in-class non-opioid therapeutic candidate for chronic pain. The trial evaluates safety, tolerability, and pharmacokinetics.
Tim Lugo, with two decades of experience in biotech finance, has been appointed CFO. Beth Seidenberg and Jim Tananbaum, venture capital veterans, have joined the board to support Latigo’s growth.
Positive Phase 1 results for LTG-001, a potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to be well tolerated with rapid absorption. Neil Singla, M.D., was appointed as Chief Medical Officer.
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board. Proceeds support advancement of company’s Nav1.8 inhibitor clinical programs and development of broader pipeline.
Latigo announced positive Phase 1 results for LTG-001, a potential best-in-class non-opioid Nav1.8 inhibitor, which was well tolerated with rapid absorption. The FDA granted Fast Track designation to LTG-001.
Timothy P. Walbert, with 30 years of biopharmaceutical industry experience and recent leadership at Horizon Therapeutics, has been appointed as chair of Latigo’s board of directors.
Latigo announced the first participant has been dosed in its Phase 1 trial of LTG-305, a potential best-in-class non-opioid therapeutic candidate for chronic pain. The trial evaluates safety, tolerability, and pharmacokinetics.
Tim Lugo, with two decades of experience in biotech finance, has been appointed CFO. Beth Seidenberg and Jim Tananbaum, venture capital veterans, have joined the board to support Latigo’s growth.
Positive Phase 1 results for LTG-001, a potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to be well tolerated with rapid absorption. Neil Singla, M.D., was appointed as Chief Medical Officer.